Trial Profile
Eylea Post Marketing Surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms rPMS
- Sponsors Bayer
- 07 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 Planned primary completion date changed from 30 Nov 2018 to 31 Dec 2018.